Latest filing published 19 Dec 2025 for Royalty Pharma plc, €2.6M. Read the official filing
Not enough buy signals with a settled T+90 horizon to measure a track record yet.
George W. Lloyd, listed as chief executive, appears in our data through filings on Royalty Pharma plc shares, published by SEC (Form 4). The record holds 25 filings, for trades running from 7 May 2021 to 17 December 2025.
On the market, this insider has only sold: 20 sales, €30.6M in total. The rest of the record consists of 3 share grants. So far in 2025, the count stands at no purchases and 3 sales.
The newest entry dates from 19 December 2025: an open-market sale of €2.6M, in Royalty Pharma plc. Between a trade and the moment it shows up on SEC (Form 4), the median delay is 2 days. Section 16 rules allow two business days to file each Form 4. Selling is not necessarily a view on the stock: liquidity needs and diversification are common motives. These figures are compiled from regulatory filings published by SEC (Form 4). They describe what insiders did and are not a recommendation.
Open company profiles for insider transactions, fundamentals and analyst consensus when available.
25 of 25 declarations